We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Primary Graft Failure Identified by Early Chimerism Following DCBU Transplantation

By LabMedica International staff writers
Posted on 14 Apr 2022
Print article
Image: Umbilical cord blood has increased access to potentially curative therapy for patients with life-threatening disorders of the bone marrow and immune system (Photo courtesy of Cellsafe Biotech Group)
Image: Umbilical cord blood has increased access to potentially curative therapy for patients with life-threatening disorders of the bone marrow and immune system (Photo courtesy of Cellsafe Biotech Group)

Umbilical cord blood transplantation (UCBT) has increased access to potentially curative therapy for patients with life-threatening disorders of the bone marrow and immune system. The introduction of reduced intensity conditioning (RIC) regimens and double umbilical cord unit infusions (DUCBT) has broadened the applicability of UCBT to frailer or larger recipients.

This procedure has led to potentially curative allogeneic transplantation being accessed by thousands of patients with diseases of the bone marrow and immune system who would otherwise have been precluded for lack of a suitably HLA matched sibling or adult volunteer unrelated donor. The kinetics of chimerism after RIC DUCBT and their clinical utility are poorly understood.

Hematologists at the University College London Hospital's NHS Foundation Trust (London, UK) and their colleagues recruited 58 patients with a median age of 52 years, with overall and progression-free survivals of 59% and 52%, respectively, at two years. Non-relapse mortality was 4% at day 100, and the relapse rate was 31% at one year. Peripheral blood lineage-specific chimerism was feasible from day 7 after transplant onward.

Lineage-specific chimerism studies (peripheral blood mononuclear cells [PBMCs], B cells, T cells, and granulocytes) were performed according to local laboratory procedures on 5 to 10 mL EDTA peripheral blood samples on days 7, 14, 21, 28, 35, 60, and 100, 6 months, and 1 and 2 years to determine the relative contribution of donor and recipient to overall hematopoiesis. Complete donor chimerism was defined as marrow reconstitution of at least 90% donor origin.

The scientists reported that five patterns of chimerism were observed including (1) complete single unit dominance (39 patients), (2) sustained donor-donor mixed chimerism (three patients), (3) sustained donor-recipient mixed chimerism (five patients), (4) dominance reversion (one patient), and (5) primary graft failure (four patients). The RIC CBT trial enabled adult patients with high-risk hematologic malignancies to safely access UCBT in the UK and provided novel insights into the kinetics of donor and recipient chimerism after RIC DUCBT that are clinically relevant. Of the 21 patients who relapsed overall, 15 had stable chimerism before relapse, including 11 patients with acute leukemia, two with Hodgkin lymphoma, one with follicular lymphoma, and one with multiple myeloma.

The authors concluded that in 81% of patients achieving sustained donor engraftment in their study, a single UCB became the dominant contributor to hematopoiesis with eradication of the second UCB unit and residual recipient bone marrow, usually within the first 35 days after transplant. The study provided novel insights into the kinetics of donor and recipient chimerism after RIC DUCBT that are clinically relevant. The study was published on April 12, 2022 in the journal Blood Advances.

Related Links:
University College London Hospital's NHS Foundation Trust 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.